HSA-/PLGA-nanoparticles as diagnostic markers for hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. For curative treatment options, early diagnosis is crucial. In this context, the present invention provides a new contrast agent, made of Gd-DTPA-loaded HSA-/PLGA-nanoparticles for magnetic resonance imaging (MRI) enabling the detection of small HCC which are undetectable with current methods and improving differentiation between HCC and benign lesions in the cirrhotic lever.
Further Information: PDF
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0
Contact
Dr. Otmar Schöller
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
